Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1966 1
1968 1
1970 1
1972 2
1973 1
1974 3
1975 4
1976 8
1977 6
1978 8
1979 11
1980 12
1981 14
1982 24
1983 28
1984 39
1985 44
1986 46
1987 63
1988 41
1989 65
1990 82
1991 76
1992 77
1993 88
1994 90
1995 91
1996 96
1997 110
1998 90
1999 122
2000 134
2001 171
2002 196
2003 237
2004 234
2005 233
2006 278
2007 286
2008 250
2009 287
2010 354
2011 380
2012 395
2013 407
2014 461
2015 545
2016 631
2017 630
2018 648
2019 701
2020 858
2021 935
2022 930
2023 873
2024 333

Text availability

Article attribute

Article type

Publication date

Search Results

11,207 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Lymphoproliferative Disorder"
Page 1
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Hallek M, Al-Sawaf O. Hallek M, et al. Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367. Am J Hematol. 2021. PMID: 34625994 Free article. Review.
The CLL international prognostic index integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. ...Alternative therapies are needed for patients with BTK and BCL2 inhibitor double-refractory disease....
The CLL international prognostic index integrates genetic, biological, and clinical variables to identify distinct risk groups of pat …
Immunotherapy in pediatric acute lymphoblastic leukemia.
Inaba H, Pui CH. Inaba H, et al. Cancer Metastasis Rev. 2019 Dec;38(4):595-610. doi: 10.1007/s10555-019-09834-0. Cancer Metastasis Rev. 2019. PMID: 31811553 Free PMC article. Review.
For immunotherapy, the approval of antibody-based therapy (with blinatumomab in 2014 and inotuzumab ozogamicin in 2017) and T cell-based therapy (with tisagenlecleucel in 2017) by the US Food and Drug Administration has significantly improved the response rate and outcomes in pat …
For immunotherapy, the approval of antibody-based therapy (with blinatumomab in 2014 and inotuzumab ozogamicin in 2017) and T cell-based the …
Primary CNS Lymphoma.
Grommes C, DeAngelis LM. Grommes C, et al. J Clin Oncol. 2017 Jul 20;35(21):2410-2418. doi: 10.1200/JCO.2017.72.7602. Epub 2017 Jun 22. J Clin Oncol. 2017. PMID: 28640701 Free PMC article. Review.
However, despite recent progress, results after treatment are durable in half of patients, and therapy can be associated with late neurotoxicity. PCNSL is an uncommon tumor, and only four randomized trials and one phase III trial have been completed so far, all in t …
However, despite recent progress, results after treatment are durable in half of patients, and therapy can be associated with late neurotoxi …
Tabelecleucel: First Approval.
Keam SJ. Keam SJ. Mol Diagn Ther. 2023 May;27(3):425-431. doi: 10.1007/s40291-023-00648-z. Epub 2023 Apr 5. Mol Diagn Ther. 2023. PMID: 37016096 Review.
Tabelecleucel has been developed by Atara Biotherapeutics under a license from Memorial Sloan-Kettering Cancer Center (MSKCC) for the treatment of lymphoproliferative disorders (LPDs), including rituximab relapsed/refractory EBV(+) post-transplant lymphopr …
Tabelecleucel has been developed by Atara Biotherapeutics under a license from Memorial Sloan-Kettering Cancer Center (MSKCC) for the treatm …
How I treat posttransplant lymphoproliferative disorder.
Amengual JE, Pro B. Amengual JE, et al. Blood. 2023 Oct 26;142(17):1426-1437. doi: 10.1182/blood.2023020075. Blood. 2023. PMID: 37540819
Posttransplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid organ transplant and hematopoietic stem cell transplant (HSCT). ...Recently, the introduction of adoptive immunotherapies has become a promising …
Posttransplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid orga …
Bortezomib for the treatment of multiple myeloma.
Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Scott K, et al. Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD010816. doi: 10.1002/14651858.CD010816.pub2. Cochrane Database Syst Rev. 2016. PMID: 27096326 Free PMC article. Review.
The first-in-class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma, either as single agent or combined with other therapies. ...SEARCH METHODS: We searched MEDLINE, the Cochrane Central Register of Controll …
The first-in-class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma …
Carfilzomib.
Kortuem KM, Stewart AK. Kortuem KM, et al. Blood. 2013 Feb 7;121(6):893-7. doi: 10.1182/blood-2012-10-459883. Blood. 2013. PMID: 23393020 Free article. Review.
Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completio …
Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior th …
BRAF in the cross-hairs.
Geyer MB, Abdel-Wahab O, Tallman MS. Geyer MB, et al. Expert Rev Hematol. 2019 Mar;12(3):183-193. doi: 10.1080/17474086.2019.1583553. Epub 2019 Feb 26. Expert Rev Hematol. 2019. PMID: 30782032 Free PMC article. Review.
Hairy cell leukemia (HCL) is a rare, chronic B-cell lymphoproliferative disorder characterized by distinctive morphologic features and an indolent clinical course. ...Areas covered: Herein the authors review the role of BRAF V600E and RAF-MEK-ERK signaling in …
Hairy cell leukemia (HCL) is a rare, chronic B-cell lymphoproliferative disorder characterized by distinctive morphologic feat …
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH. Armand P, et al. Blood. 2023 Sep 7;142(10):878-886. doi: 10.1182/blood.2022019386. Blood. 2023. PMID: 37319435 Free PMC article.
Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response …
Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activi …
Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.
Al Hamed R, Bazarbachi AH, Mohty M. Al Hamed R, et al. Bone Marrow Transplant. 2020 Jan;55(1):25-39. doi: 10.1038/s41409-019-0548-7. Epub 2019 May 14. Bone Marrow Transplant. 2020. PMID: 31089285 Review.
In the setting of immunocompromise as is the case post transplantation, the virus can reactivate and cause one of the deadliest complications post hematopoietic stem cell transplantation (HSCT), post-lymphoproliferative disease (PTLD), the incidence of which has been incre …
In the setting of immunocompromise as is the case post transplantation, the virus can reactivate and cause one of the deadliest complication …
11,207 results
You have reached the last available page of results. Please see the User Guide for more information.